ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 487

ARE ANTI-Citrullinated Protein Antibody Levels Associated with Periodontal Disease in Rheumatoid Arthritis?

Jerián González Febles1, Fernando Sánchez-Alonso2, Jorge Luis Garnier Rodríguez3, Mariano Sanz Alonso1, Federico Díaz-González4 and Beatriz Rodriguez Lozano5,6, 1Periodontology, Universidad Complutense de Madrid, Madrid, Spain, 2Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, 3Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, 4Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Rheumatology, Rheumatology Department. Hospital Universitario de Canarias, S/C TENERIFE, Spain, 6Rheumatology, Hospital de Canarias, S/C Tenerife, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ACPA, P. Gingivalis, Periodontitis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Positivity of anti-citrullinated peptides antibodies (ACPA) indicates severity in Rheumatoid Arthritis (RA). There is evidence for chronic periodontitis (PD) in RA autoimmune response by periodontopathogenic bacteria, through protein citrullination. Thus, our objectives were: 1.To determine whether there is an association between PD and its severity with ACPA(+).2.To assess relationship between PD and ACPA titres.3.To identify association between certain periodontal parameters and ACPA titres and their possible cut-off points.

Methods: Cross-sectional study RA patients ≥18 yo with ≥4 teeth, no tooth cleaning, antibiotic intake 6 months before. Comorbidities, demographics, DAS-28(ESR), DAS-28(CRP)and SDAI were taken. Serum ACPA detection: Ab IgG against CCP2 (ELISA) Immunoscan CCPlus®test kit Euro Diagnostica: positive≥25 U/mL; ACPA titres stratification: Low (25–75), moderate (76–300) and high (>300). Periodontal parameters: plaque index (PI), bleeding on probing (Bop), probing pocket depth, clinical attachment level (CAL). CAL loss was categorized according to European Workshop 2005 (Tonetti):T level0 (absence), TL1 (mild), TL2 (severe). Statistical analysis: t-student, Kruskal Wallis, Chi- squared tests.

Results:

187 RA patients included (table 1), ACPA determined in 168 patients: 67.86% (+) with similar titres distribution: low 18%, moderate 26%, high 23%. PD:182 patients (97.3%): TL1 52.4%, TL2 44.9%. Although prevalence of severe PD/ACPA(+) was higher compared to PD/ACPA(-) (69.2% vs 30.7%), there was no association between PD and ACPA positivity/titres. Regarding the association with periodontal parameters, there was tendency of association between ACPA(+) and number of periodontal pockets ≥5mm, adjusted OR 1.02 (95% CI 0.9–1.04). However, there was a gradient effect, where number of pockets ≥ 5mm increased as ACPA titles increased, which was significant for high ACPA titres (p≤0.05,OR 1.03 95% CI 1.0–1.05). Moreover, RA patients who have 15 pockets ≥ 5mm showed 1.789-fold risk of having high ACPA titres (95% CI 0.928-3.448, p 0.082). In the lineal regression analysis, a statistically significant increase of 6.946 U/mL (95% CI 2.271-11.621) was found for each pocket ≥5mm in RA patients with moderate-high disease activity (p 0.004, adjusted by age, gender and smoking). When ACPA(+) was related to %PI and BoP, a strong association was observed for PI, OR 10.32 (p<0,026), and only a tendency for BoP (p<0.062). A risk for ACPA(+) was detected with cut-off points of 8%(OR 2.19) PI and 65% BoP (OR 2.45).

Conclusion: 1.Despite higher prevalence of severe PD in ACPA(+) patients, we found no association between the presence of PD and ACPA positivity nor with serum titres. 2. On analysis of ACPA titres in relation to the severity of the periodontal parameters, there was a “gradient” risk, where number of pockets ≥5mm increased as ACPA titres increased, which was significant for high ACPA titres.3. There was a lineal correlation between ACPA titres and number of pockets ≥5mm.


Disclosure: J. González Febles, None; F. Sánchez-Alonso, None; J. L. Garnier Rodríguez, None; M. Sanz Alonso, None; F. Díaz-González, None; B. Rodriguez Lozano, None.

To cite this abstract in AMA style:

González Febles J, Sánchez-Alonso F, Garnier Rodríguez JL, Sanz Alonso M, Díaz-González F, Rodriguez Lozano B. ARE ANTI-Citrullinated Protein Antibody Levels Associated with Periodontal Disease in Rheumatoid Arthritis? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/are-anti-citrullinated-protein-antibody-levels-associated-with-periodontal-disease-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-anti-citrullinated-protein-antibody-levels-associated-with-periodontal-disease-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology